Effectiveness and safety of tocilizumab in patients with systemic sclerosis: a propensity score matched controlled observational study of the EUSTAR cohort
Objectives Tocilizumab showed trends for improving skin fibrosis and prevented progression of lung fibrosis in systemic sclerosis (SSc) in randomised controlled clinical trials. We aimed to assess safety and effectiveness of tocilizumab in a real-life setting using the European Scleroderma Trial and...
Similar Items
-
The burden of systemic sclerosis in Switzerland – the Swiss systemic sclerosis EUSTAR cohort
by: Jasmin Hernández, et al.
Published: (2021-07-01) -
Does regression of skin thickening predict improvement of internal organ involvement and survival in patients with diffuse cutaneous systemic sclerosis? A EUSTAR analysis
by: Anja Wyss, et al.
Published: (2024-10-01) -
Incidences and Risk Factors of Organ Manifestations in the Early Course of Systemic Sclerosis: A Longitudinal EUSTAR Study.
by: Veronika K Jaeger, et al.
Published: (2016-01-01) -
Therapeutic management of fibrosis in systemic sclerosis patients – an analysis from the Swiss EUSTAR cohort
by: Kevin Windirsch, et al.
Published: (2024-02-01) -
Systemic sclerosis associated interstitial lung disease - individualized immunosuppressive therapy and course of lung function: results of the EUSTAR group
by: Sabine Adler, et al.
Published: (2018-01-01)